Scancell

About:

Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.

Website: http://www.scancell.co.uk

Twitter/X: scancellpharma

Top Investors: Oxford Capital, Calculus Capital, Oxford Technology Management, Redmile Group, Hygea VCT

Description:

Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.